Drylab AI Secured $3 Million in Seed Funding
The research automation startup plans to scale its autonomous agent platform for global laboratory environments.
Updated on Oct. 13, 2026 in Biotech
Live Poll
Do you trust autonomous AI agents to conduct scientific research accurately and reliably?
Drylab AI has raised $3 million in a seed funding round led by Vertex Ventures with participation from PatSnap. The company, which launched in February 2026, provides autonomous agents that integrate with research platforms.
Why it matters
The company aims to expand its headcount and obtain security certifications, signaling a move to capture enterprise-level research organizations. This funding follows the company's efforts to scale its software-integrated science tools across international markets.
The Drylab AI platform integrates over 800 scientific tools and databases into a single interface. These automated systems are designed to support research workflows across users currently located in the United States, Europe, and Asia.
The players
Drylab AI
A Singapore-based startup building autonomous agent technology for scientific research and laboratory automation.
Vertex Ventures
A global venture capital firm focusing on early-stage technology investments in enterprise and deep-tech sectors.
PatSnap
An innovation intelligence platform that provides data and analytics on patent and R&D activities for global research organizations.
The details
The platform functions by deploying autonomous agents — specialized AI software that performs tasks independently — to select and execute experiments from integrated scientific datasets. As these agents run, the model analyzes output data from previous research sessions to refine its logic and iterative approach to new experiments.
Timeline
February 2026: Drylab AI launched its research platform.
October 13, 2026: The company announced the closing of its $3 million seed round.
The Tech Race
Drylab AI follows the industry trend toward software-defined research environments that move beyond manual data entry. By aggregating 800 tools, the company competes with specialized research software providers aiming to automate the full life cycle of scientific investigation.
Professional research teams in the U.S., Europe, and Asia can currently utilize the platform to bridge disparate scientific databases. The startup plans to hire additional engineering and biology staff to accelerate feature updates following this round of capital.
The takeaway
The funding highlights an increasing demand for agentic systems that can navigate complex scientific datasets without human intervention. Observers should track the company's progress toward achieving enterprise security certifications, which will be the primary barrier to adoption in institutional labs.
Further reading
Learn more about the latest innovations in Biotech research and automation.
Source note: This article includes information reported by The Business Times.
Live Poll
Do you trust autonomous AI agents to conduct scientific research accurately and reliably?
